Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Purchases $26,078.98 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc bought 1,093 shares of Surrozen stock in a transaction that occurred on Thursday, February 12th. The stock was bought at an average price of $23.86 per share, for a total transaction of $26,078.98. Following the completion of the acquisition, the insider directly owned 651,114 shares of the company’s stock, valued at $15,535,580.04. The trade was a 0.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The stock was purchased at an average price of $23.57 per share, for a total transaction of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The shares were acquired at an average price of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The shares were acquired at an average cost of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The stock was bought at an average price of $21.39 per share, with a total value of $91,356.69.

Surrozen Trading Down 1.4%

Surrozen stock traded down $0.36 during midday trading on Friday, reaching $24.48. The stock had a trading volume of 53,087 shares, compared to its average volume of 131,820. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $25.84. The company has a fifty day moving average price of $21.51 and a two-hundred day moving average price of $15.65. The company has a market capitalization of $209.82 million, a P/E ratio of -1.10 and a beta of 0.58.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SRZN. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Hedge Funds Weigh In On Surrozen

Several hedge funds have recently made changes to their positions in the stock. Stempoint Capital LP increased its holdings in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after purchasing an additional 445,713 shares during the period. Braidwell LP bought a new stake in Surrozen during the second quarter valued at $1,252,000. Stonepine Capital Management LLC grew its position in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after buying an additional 20,247 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the last quarter. Finally, Empery Asset Management LP purchased a new stake in shares of Surrozen in the 4th quarter valued at about $2,350,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.